Strides Pharma Science Limited

NSE: STAR · Healthcare

₹999.60-0.79%06 Nov 2026

Ask the data

Instant answers about Strides Pharma Science Limited — computed from its filings, no language model

Market cap₹9,214 cr

Current price₹999.60

High / Low₹1,235 / ₹794

P/E14.9

P/B2.70

Book value₹370.7

ROE18.1%

ROCE17.4%

Debt / equity0.54

Dividend yield0.40%

EPS (TTM)₹66.92

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	2,839	3,012	2,752	3,316	3,070	3,688	4,051	4,565	4,859
EBITDA	397	455	516	635	-20	430	743	803	925
Operating margin	14.0%	15.1%	18.7%	19.1%	-0.7%	11.7%	18.3%	17.6%	19.0%
Interest	196	205	156	150	177	261	314	249	179
Depreciation	154	172	174	206	233	243	221	192	202
Profit before tax	97	120	162	373	-542	-1	59	485	668
Tax	10	13	11	32	-178	-55	32	78	94
Net profit	660	325	36	268	-460	-203	-71	3,593	556
EPS ₹	73.81	36.25	4.06	29.96	-51.28	-22.49	-7.76	390.54	60.34
Operating cash flow	—	—	—	—	-258	44	701	684	703
Capex	—	—	—	—	143	95	118	242	423
Dividend paid	—	—	—	—	22	0	14	23	37
Total assets	—	—	—	—	—	6,638	5,840	6,049	6,927
Equity	—	—	—	—	—	2,212	2,126	2,552	3,108

Quarterly performance

last 34 quarters · ₹ crore

showing latest 8 of 34 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	664	663	733	794	840	686	715	732	619	782	794	832	908	688	721	866	940	897	865	986	930	999	1,038	1,084	1,088	1,201	1,154	1,190	1,120	1,221	1,195	1,323	1,265	1,430
Operating profit	87	81	100	127	159	121	148	182	65	155	162	161	157	-50	-14	42	60	98	116	156	167	153	194	230	217	236	210	218	218	232	236	240	230	251
Operating margin	13.0%	12.2%	13.6%	16.0%	18.9%	17.6%	20.7%	24.9%	10.5%	19.8%	20.4%	19.3%	17.3%	-7.3%	-1.9%	4.9%	6.4%	10.9%	13.5%	15.8%	17.9%	15.3%	18.7%	21.2%	20.0%	19.6%	18.2%	18.3%	19.5%	19.0%	19.7%	18.1%	18.2%	17.5%
Other income	22	11	8	1	15	10	13	12	18	12	13	13	13	14	22	86	14	23	26	27	9	36	9	-14	13	28	6	12	9	27	107	8	5	4
Interest	45	44	48	50	63	35	40	40	40	37	37	35	42	41	44	49	55	68	58	81	76	79	79	80	80	82	52	50	47	46	43	42	41	47
Depreciation	44	43	44	41	44	43	42	43	45	49	53	53	52	55	57	61	60	62	60	61	60	60	51	50	49	51	48	49	49	50	51	53	56	57
Profit before tax	-3	-1	7	38	76	46	162	127	-173	126	98	73	76	-225	-151	-59	-107	7	65	34	33	-115	62	78	97	128	113	103	122	154	246	147	201	150
Tax	-4	-4	2	6	11	3	7	11	-10	3	6	11	11	-36	-7	-131	-28	-38	4	7	10	-7	10	19	17	21	24	21	16	22	37	19	34	16
Net profit	568	-6	-12	293	48	4	143	94	-204	104	81	38	46	-205	-163	29	-136	23	-80	-10	-7	-131	50	18	70	93	88	82	100	128	202	127	157	131
EPS ₹	63.45	-0.66	-1.34	32.77	5.31	0.41	15.94	10.48	-22.77	11.56	9.03	4.22	5.14	-22.88	-18.12	3.25	-15.13	2.54	-8.86	-1.06	-0.79	-14.54	5.43	1.98	7.64	10.14	9.56	8.92	10.81	13.84	21.93	13.77	17.02	14.19
Revenue YoY	—	—	—	—	26.4%	3.4%	-2.4%	-7.8%	-26.3%	14.0%	11.0%	13.6%	46.9%	-12.0%	-9.1%	-4.7%	36.6%	24.3%	—	13.9%	-1.1%	11.4%	20.0%	9.9%	16.9%	20.2%	11.2%	9.8%	3.0%	1.6%	3.6%	11.2%	13.0%	17.1%
Profit YoY	—	—	—	—	-91.6%	—	—	-68.0%	-529.2%	2698.9%	-43.3%	-59.7%	—	-298.1%	-300.8%	-36.6%	—	—	—	-132.6%	—	-675.5%	—	—	—	—	77.1%	352.1%	41.9%	36.8%	129.8%	54.4%	57.5%	2.6%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Strides Pharma Science Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	720	743	885	929	2,203	2,134
Operating profit	97	96	115	134	281	279
Operating margin	13.5%	12.9%	13.0%	14.4%	12.8%	13.1%
Other income	—	136	1,458	100	142	176
Interest	68	62	93	34	103	115
Depreciation	18	24	38	49	106	127
Profit before tax	82	116	4,584	669	189	135
Tax	5	1	1,102	137	28	27
Net profit	77	116	3,481	532	161	109

Quarters

showing latest 8 of 39 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	MAR '09†	JUN '09†	SEP '09†	MAR '10†	JUN '10†	SEP '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	106	76	120	161	191	186	176	170	133	120	136	128	201	197	198	124	200	188	177	178	166	209	253	257	201	217	242	270	219	259	1,055	670	514	517	580	523	537	588	298
Operating profit	4	-43	-0	25	32	49	20	24	30	20	21	21	39	6	44	9	27	28	9	32	22	35	28	30	32	32	27	43	25	20	127	109	68	50	77	84	16	40	-2
Operating margin	3.7%	-57.0%	-0.1%	15.7%	16.7%	26.3%	11.2%	13.9%	22.4%	16.7%	15.2%	16.6%	19.5%	2.8%	22.1%	7.1%	13.6%	15.0%	5.0%	18.0%	13.3%	16.8%	10.9%	11.7%	16.1%	14.7%	11.1%	15.8%	11.4%	7.7%	12.1%	16.3%	13.3%	9.6%	13.3%	16.1%	2.9%	6.8%	-0.8%
Other income	10	4	1	9	—	—	—	—	1	—	—	—	—	—	45	9	25	11	84	17	18	17	1,388	35	25	27	27	20	68	26	36	11	35	47	36	57	44	39	58
Interest	7	14	12	9	9	16	15	16	17	20	21	18	21	21	17	9	24	17	9	12	16	25	40	12	9	10	7	9	8	9	52	34	29	29	28	29	37	36	22
Depreciation	5	5	5	5	5	4	5	5	3	3	3	4	4	4	6	4	4	4	6	9	9	9	10	10	11	13	12	13	14	14	48	30	29	31	33	34	34	35	21
Profit before tax	2	-139	-16	-56	-52	22	60	-2	13	-14	11	16	20	-70	161	-28	-20	30	78	28	2	5	4,643	-67	38	421	123	87	68	17	51	54	30	33	-20	92	8	3	20
Tax	2	-6	0	0	0	0	0	-6	3	0	0	3	5	-5	5	0	0	0	4	-3	0	3	1,118	-18	11	83	25	18	20	7	7	-6	3	2	4	17	-1	-10	-84
Net profit	0	-133	-16	-56	-52	21	60	4	10	-14	11	13	15	-65	156	-28	-20	30	74	32	2	2	3,525	-48	27	338	97	70	48	9	44	60	27	31	-25	75	9	13	104
EPS ₹	-0.18	-38.36	-4.69	-14.51	-13.12	5.15	14.80	0.84	2.23	-3.32	2.18	2.21	2.52	-11.21	26.68	-4.82	-3.39	5.13	12.58	5.36	0.37	0.38	597.00	-8.10	4.50	56.82	16.35	11.69	8.06	1.56	5.41	6.68	3.04	3.44	-2.74	8.41	1.00	1.40	11.64
Revenue YoY	—	—	—	—	80.1%	55.4%	9.3%	-11.1%	-28.7%	-31.9%	-19.9%	-3.5%	67.8%	45.0%	—	-2.9%	-0.5%	-4.7%	-10.3%	43.6%	-16.7%	11.3%	42.8%	43.9%	20.7%	3.8%	-4.6%	5.2%	9.2%	19.6%	336.3%	148.1%	134.4%	99.2%	-45.0%	-22.0%	4.5%	13.9%	-48.7%
Profit YoY	—	—	—	—	-20772.0%	—	—	—	-53.1%	-122.6%	151.8%	26.5%	—	-712.2%	—	-321.0%	-236.2%	—	-52.5%	—	—	-92.7%	4668.3%	-252.9%	1140.7%	15215.4%	-97.2%	—	79.2%	-97.2%	-54.7%	-14.4%	-43.4%	229.6%	-155.6%	26.0%	-67.1%	-59.1%	—

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 28 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	—	—	—	—	—	—	—	—	—	—	—	—	-7.0%	-9.2%	-3.3%	-11.1%	-4.8%	-3.3%	0.3%	10.2%	11.9%	13.1%	14.2%	14.4%	18.6%	17.9%	19.7%	18.1%
ROCE	—	—	—	—	—	—	—	—	—	—	—	—	2.6%	5.2%	8.5%	6.6%	7.0%	8.2%	9.7%	15.3%	15.8%	16.2%	16.1%	15.3%	18.0%	17.7%	19.2%	17.4%
Net margin	29.5%	10.7%	10.9%	16.1%	9.7%	1.3%	4.8%	2.5%	0.6%	8.1%	-1.3%	-9.0%	-4.6%	-5.5%	-2.0%	-6.0%	-2.5%	-1.7%	0.2%	5.2%	6.0%	7.2%	7.8%	8.5%	10.8%	11.4%	12.3%	11.8%
EBITDA margin	13.8%	15.4%	16.6%	18.3%	20.5%	18.7%	19.3%	19.3%	17.9%	19.1%	13.3%	8.1%	8.9%	11.7%	14.6%	15.6%	16.9%	18.3%	18.9%	19.9%	19.7%	19.0%	18.9%	18.7%	19.1%	19.0%	18.7%	18.3%
Debt / equity	—	—	—	—	—	—	—	—	—	—	—	—	1.24	1.25	1.25	1.30	1.30	1.14	1.14	0.98	0.98	0.70	0.70	0.63	0.63	0.54	0.54	0.54
Interest coverage	1.22	1.59	1.85	2.71	3.31	2.04	2.54	2.16	1.84	3.49	1.15	-0.41	0.59	1.00	1.49	1.06	1.05	1.19	1.38	2.13	2.41	2.66	3.01	3.51	4.34	4.74	5.35	5.32
Asset turnover	—	—	—	—	—	—	—	—	—	—	—	—	0.52	0.56	0.55	0.60	0.62	0.69	0.72	0.74	0.76	0.77	0.77	0.72	0.72	0.70	0.72	0.70

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 9 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	90	90	90	92	92	92	92	92	92
Other equity / reserves	2,241	2,122	1,963	2,034	2,179	2,460	2,664	3,015	3,324
Total equity	2,331	2,212	2,054	2,126	2,271	2,552	2,756	3,108	3,416
Borrowings	2,896	2,774	2,673	2,415	2,215	1,796	1,749	1,669	1,847
Current liabilities	3,305	2,990	2,982	2,879	2,964	2,592	2,890	2,895	3,135
Non-current liabilities	1,238	1,475	1,206	889	811	871	827	882	883
Total assets	6,845	6,638	6,338	5,840	5,990	6,049	6,521	6,927	7,489
Property, plant & equipment	1,348	1,324	927	879	845	881	882	992	958
Capital work-in-progress	39	48	46	80	154	100	164	161	226
Investments	622	490	416	303	243	409	440	291	346
Inventories	1,134	1,147	1,138	1,126	1,211	1,278	1,459	1,635	1,873
Receivables	1,199	1,299	1,232	1,142	1,237	1,203	1,130	1,289	1,464
Cash & equivalents	111	304	99	161	131	113	123	189	137

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	-258	44	701	684	703
Cash from investing	-119	302	-150	-90	-173
Cash from financing	421	-214	-693	-643	-453
Capex	143	95	118	242	423
Free cash flow	-401	-51	583	442	280
Dividends paid	22	0	14	23	37

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹958 cr13%

CWIP

₹226 cr3%

Investments

₹346 cr5%

Inventories

₹1,873 cr25%

Receivables

₹1,464 cr20%

Cash & equivalents

₹137 cr2%

Other assets

₹2,483 cr33%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Strides Pharma Science Limited	9,214	999.60	14.9	2.70	18.1%

StoxGud checklist: Bullish setup · 8/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-9.2%

6 months-12.8%

1 year+17.5%

3Y CAGR+27.5%

5Y CAGR+12.7%

10Y CAGR-0.9%

50-day avg₹1,097.70

200-day avg₹1,021.50

RSI (14)41

FAQs

What is the share price of Strides Pharma Science Limited?

Strides Pharma Science Limited (STAR) closed at ₹999.60 on NSE on 06 Nov 2026.

What is the market cap of Strides Pharma Science Limited?

₹9,214 crore at the latest close.

What is the P/E ratio of Strides Pharma Science Limited?

14.9, on trailing-twelve-month earnings from its filings.

How fast is Strides Pharma Science Limited growing?

Strides Pharma Science Limited: revenue has compounded at 9.6% a year over three years. Latest-quarter revenue is up 17.1% year on year, profit up 2.6%.

How profitable is Strides Pharma Science Limited?

On a trailing-twelve-month basis return on equity is 18.1%, return on capital employed 17.4%, operating margin 18.3%, net margin 11.8%.

How much debt does Strides Pharma Science Limited have?

Strides Pharma Science Limited is moderately geared: debt to equity is 0.54 with borrowings of ₹1,847 cr against cash of ₹137 cr (balance sheet of 2026-09-30). Operating profit covers interest 5.3 times.

Financials parsed from Strides Pharma Science Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.